A

Amylyx Pharmaceuticals

Biopharmaceutical company developing neurodegenerative therapies

Senior Director - Toxicology

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • A PhD in Toxicology, Pharmacology, Molecular or Cell Biology, or a related science is required.
  • A minimum of 10–12 years of industry experience in toxicology and nonclinical drug development following completion of a PhD or postdoctoral work is required.
  • Demonstrated experience developing and executing nonclinical safety strategies to support drug discovery, candidate selection, IND-enabling studies, regulatory submissions, and clinical development is required.
  • Broad knowledge of toxicology and practical knowledge of pharmaceutical toxicology are required.
  • Expert-level knowledge of global preclinical and clinical regulatory guidelines, including experience authoring, reviewing, and contributing to regulatory submissions and interactions with global health authorities, is required.
  • The ability to interpret complex toxicology and nonclinical data and translate findings into actionable development strategies is required.
  • Extensive experience leading external contract research organizations, consultants, and multidisciplinary scientific teams to deliver nonclinical development objectives is required.
  • Demonstrated success working in cross-functional program teams is required.
  • Strong organizational skills and the ability to communicate scientific concepts in writing, verbally, and through presentations to diverse audiences, including executive leadership, are required.
  • The employee must be able to work in a setting that meets role requirements, including privacy, reliable internet access, telephone access, and video conferencing capability.

Responsibilities

  • Develop and execute comprehensive nonclinical safety strategies for clinical candidate selection, IND-enabling activities, regulatory submissions, and clinical development across programs involving small molecules, peptides, protein-based biologics, and antisense oligonucleotides.
  • Interpret toxicology, safety pharmacology, developmental and reproductive toxicology, and related nonclinical data and study types to inform development decisions and risk-benefit assessments.
  • Lead the design, oversight, and scientific interpretation of outsourced toxicology and safety studies conducted at contract research organization partners.
  • Represent toxicology on cross-functional project teams as the primary toxicology expert.
  • Author and review regulatory documents, including INDs, briefing packages, investigator brochures, NDAs, and MAAs, and respond to health-authority inquiries.
  • Establish and maintain relationships with external scientific experts, key opinion leaders, and regulatory consultants to support program objectives.
  • Ensure toxicology strategy aligns with global regulatory expectations and industry best practices.
  • Identify and proactively manage safety-related risks, lead investigative toxicology as needed, and provide recommendations and mitigation strategies to project teams and senior leadership.
  • Contribute to portfolio prioritization by integrating toxicology risk, development feasibility, and program value considerations.
  • Represent the sponsor in nonclinical study execution at contract research organization partners across nonclinical study types, including developmental and reproductive toxicology.
  • Mentor and develop scientific talent and foster accountability, collaboration, and continuous learning.
  • Travel to the corporate location in Cambridge, Massachusetts several times a year and attend other company-related events as requested.

Desired Qualifications

  • DABT certification is desirable.
  • Direct experience with targeted delivery approaches, rare-disease development, and endocrine and/or neuromuscular indications is desirable.

About the Company

Amylyx Pharmaceuticals

Biopharmaceutical company developing neurodegenerative therapies

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, with a focus on ALS and Alzheimer's disease. Its main asset is AMX0035, currently in clinical trials, including the CENTAUR study for ALS and the PEGASUS study for late mild cognitive impairment or early dementia due to Alzheimer’s disease. The company advances products through rigorous, randomized, double-blind, placebo-controlled trials to demonstrate safety and efficacy before pursuing commercialization. In addition to research, Amylyx engages in awareness and community campaigns to support patients, caregivers, and researchers. The company aims to bring validated therapies to market to improve patient outcomes and generate revenue by selling treatments to healthcare providers and patients.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2013

Recently Posted Jobs

Explore more opportunities at Amylyx Pharmaceuticals

See more jobs